Fausto Rojas-Durán

Dr. Fausto Rojas-Durán

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2022 in NeuroSci
Verified
Journal Article
Open access
PDF file
SLSandra Yasbeth Lara
Sandra Yasbeth Lara
ÁFÁngel de Jesús Laureani Fierro
Ángel de Jesús Laureani Fierro
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
María Rebeca Toledo-CardenasMaría Rebeca Toledo-Cardenas
María Rebeca Toledo-Cardenas
Luis I. GarcíaLuis I. García
Luis I. García
CECESAR ANTONIO PEREZ ESTUDILLO
CESAR ANTONIO PEREZ ESTUDILLO
For years, the biochemical processes that are triggered by harmful and non-harmful stimuli at the central nervous system level have been extensively studied by the scientific community through numerous techniques and animal models. For example, one of these techniques is the use of immediate expression genes, which is a useful, accessible, and reliable method for observing and quantifying cell activation. It has been shown that both the c-fos gene and its protein c-Fos have rapid activation after stimulus, with the length of time that they remain active depending on the type of stimulus and the activation time depending on the stimulus and the structure studied. Fos requires the participation of other genes (such as c-jun) for its expression (during hetero-dimer forming). c-Fos dimerizes with c-Jun protein to form factor AP-1, which promotes the transcription of various genes. The production and removal of c-Fos is part of cellular homeostasis, but its overexpression results in increased cell proliferation. Although Fos has been used as a marker of cellular activity since the 1990s, which molecular mechanism participates in the regulation of the expression of this protein is still unknown because the gene and the protein are not specific to neurons or glial cells. For these reasons, this work has the objective of gathering information about this protein and its use in neuroscience.

1 July 2020 in Medical Hypotheses
Verified
Journal Article
Closed access
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
Deissy Herrera-CovarrubiasDeissy Herrera-Covarrubias
Deissy Herrera-Covarrubias
FRFausto Rojas-Durán
Fausto Rojas-Durán

10 October 2020 in Pharmacological Reports
Verified
Journal Article
Open access
PDF file
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
JAJosé D. Aranda-Martínez
José D. Aranda-Martínez
RARamiro Araújo
Ramiro Araújo
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
Deissy Herrera-CovarrubiasDeissy Herrera-Covarrubias
Deissy Herrera-Covarrubias
FRFausto Rojas-Durán
Fausto Rojas-Durán
Background We conducted an observational study of 15 patients from a Southeastern area of Mexico with symptoms compatible with SARS-Cov-2, which were treated with the antiviral amantadine. Methodology In this study, data were collected from 15 individuals with clinical symptoms of COVID-19 infection, which were treated on an ambulatory basis with 100 mg of amantadine for a period of 14 days. Results This drug demonstrated its effectiveness, as patients recovered successfully with this treatment without the necessity of attending a hospital to use mechanical ventilation. All patients developed IgG antibodies to SARS-Cov-2. Conclusion Amantadine can be used as a viable and cost-effective alternative for treating people with severe acute respiratory syndrome (SARS-Cov-2) on an ambulatory basis, while the vaccine is not available.

17 May 2006 in Reproductive Biology and Endocrinology
Verified
Journal Article
Open access
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
ASAbraham Soto-Cid
Abraham Soto-Cid
FRFausto Rojas-Durán
Fausto Rojas-Durán
LPLuz I Pascual
Luz I Pascual
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
Jorge ManzoJorge Manzo
Jorge Manzo
The prostate is a key gland in the sexual physiology of male mammals. Its sensitivity to steroid hormones is widely known, but its response to prolactin is still poorly known. Previous studies have shown a correlation between sexual behaviour, prolactin release and prostate physiology. Thus, here we used the sexual behaviour of male rats as a model for studying this correlation. Hence, we developed experimental paradigms to determine the influence of prolactin on sexual behaviour and prostate organization of male rats. In addition to sexual behaviour recordings, we developed the ELISA procedure to quantify the serum level of prolactin, and the hematoxilin-eosin technique for analysis of the histological organization of the prostate. Also, different experimental manipulations were carried out; they included pituitary grafts, and haloperidol and ovine prolactin treatments. Data were analyzed with a One way ANOVA followed by post hoc Dunnet test if required. Data showed that male prolactin has a basal level with two peaks at the light-dark-light transitions. Consecutive ejaculations increased serum prolactin after the first ejaculation, which reached the highest level after the second, and started to decrease after the third ejaculation. These normal levels of prolactin did not induce any change at the prostate tissue. However, treatments for constant elevations of serum prolactin decreased sexual potency and increased the weight of the gland, the alveoli area and the epithelial cell height. Treatments for transient elevation of serum prolactin did not affect the sexual behaviour of males, but triggered these significant effects mainly at the ventral prostate. The prostate is a sexual gland that responds to prolactin. Mating-induced prolactin release is required during sexual encounters to activate the epithelial cells in the gland. Here we saw a precise mechanism controlling the release of prolactin during ejaculations that avoid the detrimental effects produced by constant levels. However, we showed that minor elevations of prolactin which do not affect the sexual behaviour of males, produced significant changes at the prostate epithelium that could account for triggering the development of hyperplasia or cancer. Thus, it is suggested that minute elevations of serum prolactin in healthy subjects are at the etiology of prostate abnormal growth.

8 March 2024 in NeuroSci
Verified
Journal Article
Open access
PDF file
David Brash-AriasDavid Brash-Arias
David Brash-Arias
Luis I. GarcíaLuis I. García
Luis I. García
CECESAR ANTONIO PEREZ ESTUDILLO
CESAR ANTONIO PEREZ ESTUDILLO
FRFausto Rojas-Durán
Fausto Rojas-Durán
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
Lizbeth Chi-CastañedaLizbeth Chi-Castañeda
Lizbeth Chi-Castañeda
The search for new therapies to reduce symptoms and find a cure for Parkinson’s disease has focused attention on two key points: the accumulation of alpha-synuclein aggregates and astrocytes. The former is a hallmark of the disease, while the latter corresponds to a type of glial cell with an important role in both the prevention and development of this neurodegenerative disorder. Traditionally, research has focused on therapies targeting dopaminergic neurons. Currently, as more is known about the genetic and molecular factors and the neuroglial interaction in the disease, great emphasis has been placed on the neuroprotective role of astrocytes in the early stages of the disease and on the astrocytic capture of alpha-synuclein under both physiological and pathological conditions. This review aims to analyze the contribution of alpha-synuclein and astrocytes to the development and progression of Parkinson’s disease, as well as to evaluate recent therapeutic proposals specifically focused on synucleopathies and astroglial cells as potential therapies for the disease.

13 May 2025 in Neurology International
Verified
Journal Article
Open access
PDF file
GAGonzalo Aranda-Abreu
Gonzalo Aranda-Abreu
FRFausto Rojas-Durán
Fausto Rojas-Durán
MHMaria Elena Hernandez-Aguilar
Maria Elena Hernandez-Aguilar
Deissy Herrera-CovarrubiasDeissy Herrera-Covarrubias
Deissy Herrera-Covarrubias
Luis I. GarcíaLuis I. García
Luis I. García
Lizbeth Chi-CastañedaLizbeth Chi-Castañeda
Lizbeth Chi-Castañeda
Tau protein plays a pivotal role in maintaining neuronal structure and function through its regulation of microtubule stability and neuronal polarity. Encoded by the MAPT gene, Tau exists in multiple isoforms due to alternative mRNA splicing, with differential expression in the central and peripheral nervous systems. In healthy neurons, tau mRNA is selectively localized and translated in axons, a process tightly regulated by untranslated regions (UTRs) and RNA-binding proteins such as HuD and FMRP. Pathologically, Tau undergoes hyperphosphorylation, misfolding, and aggregation, which contribute to neurodegeneration in a range of disorders collectively known as tauopathies. Alzheimer’s disease (AD) is the most prevalent tauopathy, where abnormal Tau accumulation in the temporal and frontal lobes correlates with cognitive decline and behavioral symptoms. Other tauopathies, including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Frontotemporal Dementia with Parkinsonism (FTDP-17), and Pick’s disease, are distinguished by the predominance of specific Tau isoforms (3R or 4R), cellular distribution, and affected brain regions. Notably, astroglial tauopathies highlight the pathological role of Tau accumulation in glial cells, expanding the understanding of neurodegeneration beyond neurons. Despite advances in imaging biomarkers (e.g., Tau-PET) and molecular diagnostics, effective disease-modifying therapies for tauopathies remain elusive. Ongoing research targets Tau through immunotherapies, splicing modulators, kinase inhibitors, and antisense oligonucleotides, aiming to mitigate Tau pathology and its deleterious effects. Understanding the multifaceted roles of Tau in neuronal and glial contexts is critical for developing future therapeutic strategies against tauopathies.